Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-6.51 Insider Own3.15% Shs Outstand156.35M Perf Week0.51%
Market Cap1.24B Forward P/E9.93 EPS next Y0.80 Insider Trans-5.31% Shs Float151.60M Perf Month-13.06%
Income-1002.24M PEG- EPS next Q0.20 Inst Own107.53% Short Float14.48% Perf Quarter-37.49%
Sales442.74M P/S2.80 EPS this Y110.57% Inst Trans-3.30% Short Ratio4.68 Perf Half Y-17.59%
Book/sh-2.21 P/B- EPS next Y16.99% ROA-127.54% Short Interest21.95M Perf Year-27.00%
Cash/sh0.59 P/C13.45 EPS next 5Y- ROE-654.88% 52W Range7.53 - 15.70 Perf YTD-30.77%
Dividend Est.- P/FCF6.77 EPS past 5Y-28.37% ROI-601.74% 52W High-49.55% Beta0.58
Dividend TTM- Quick Ratio0.84 Sales past 5Y5.56% Gross Margin99.64% 52W Low5.18% ATR (14)0.36
Dividend Ex-Date- Current Ratio0.84 EPS Y/Y TTM-668.17% Oper. Margin39.17% RSI (14)36.05 Volatility3.56% 3.70%
Employees267 Debt/Eq- Sales Y/Y TTM7.83% Profit Margin-226.37% Recom1.17 Target Price18.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-102.65% Payout- Rel Volume0.54 Prev Close7.60
Sales Surprise0.07% EPS Surprise-105.00% Sales Q/Q9.66% EarningsFeb 15 BMO Avg Volume4.70M Price7.92
SMA20-3.31% SMA50-24.45% SMA200-23.94% Trades Volume2,532,929 Change4.21%
Date Action Analyst Rating Change Price Target Change
Jan-17-24Initiated Craig Hallum Buy $21
Dec-14-23Initiated Wells Fargo Overweight $20
Nov-09-23Initiated Jefferies Buy $21
Sep-28-23Initiated JMP Securities Mkt Outperform $22
Sep-02-22Initiated CapitalOne Overweight $15
Apr-22-22Initiated Piper Sandler Overweight $16
Sep-30-20Downgrade Wells Fargo Overweight → Equal Weight $14 → $9
Jun-17-20Initiated Northland Capital Outperform $14
Jul-10-19Resumed Credit Suisse Neutral
Mar-27-19Upgrade Morgan Stanley Underweight → Equal-Weight
Today 10:39AM
Mar-28-24 07:30AM
Mar-05-24 01:05PM
Feb-29-24 04:19PM
06:26AM Loading…
Feb-23-24 07:30AM
Feb-16-24 10:15AM
Feb-15-24 10:45PM
08:50AM Loading…
Feb-05-24 08:50AM
Feb-01-24 04:01PM
Jan-23-24 09:55AM
Jan-08-24 07:00PM
Jan-03-24 04:01PM
Dec-12-23 04:01PM
Nov-30-23 09:45AM
Nov-21-23 04:01PM
Nov-10-23 02:45PM
Nov-09-23 10:25PM
07:00AM Loading…
Oct-26-23 04:01PM
Oct-23-23 07:30AM
Oct-17-23 12:02PM
Oct-16-23 06:00AM
Oct-05-23 07:30AM
Oct-03-23 11:43AM
Oct-01-23 07:15AM
Sep-26-23 11:48AM
Sep-20-23 07:36AM
Sep-19-23 12:08PM
Sep-12-23 08:32AM
Sep-07-23 11:30AM
Aug-12-23 08:50AM
Aug-09-23 09:24AM
Aug-08-23 11:12PM
Jul-28-23 02:56PM
Jul-25-23 04:01PM
Jun-29-23 08:30AM
Jun-21-23 08:00PM
Jun-16-23 07:00AM
Jun-13-23 09:18AM
Jun-12-23 04:05PM
May-25-23 10:32AM
May-23-23 12:07PM
May-22-23 05:43PM
May-09-23 04:01PM
May-08-23 07:30AM
May-05-23 09:31AM
May-04-23 08:55AM
Apr-26-23 08:00PM
Apr-24-23 07:30AM
Apr-20-23 04:01PM
Mar-22-23 02:53PM
Mar-14-23 02:56AM
Mar-02-23 07:09AM
Feb-27-23 04:01PM
Feb-20-23 07:40AM
Feb-17-23 11:11AM
Feb-16-23 08:35AM
Feb-15-23 11:09AM
Feb-14-23 10:00AM
Feb-13-23 07:30AM
Feb-10-23 07:40AM
Feb-09-23 10:01AM
Feb-04-23 09:40AM
Feb-02-23 04:01PM
Jan-23-23 11:07AM
Jan-16-23 05:36AM
Jan-09-23 06:00AM
Jan-04-23 04:01PM
Dec-09-22 11:30AM
Nov-22-22 04:01PM
Nov-09-22 07:47AM
Nov-04-22 12:13PM
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shetzline MichaelCMO,SVP,Head-Res&DrugMar 08 '24Option Exercise0.0034,9360429,847Mar 12 04:05 PM
John MinardoChief Legal OfficerMar 08 '24Option Exercise0.0032,7520311,975Mar 12 04:05 PM
MCCOURT Thomas AChief Executive OfficerMar 08 '24Option Exercise0.00120,29801,217,948Mar 12 04:05 PM
Davis AndrewSVP, Chief Business OfficerMar 08 '24Option Exercise0.0037,1200310,756Mar 12 04:05 PM
Emany Sravan KumarSVP, Chief Financial OfficerMar 08 '24Option Exercise0.0037,1200338,853Mar 12 04:05 PM
Duane Jon RDirectorMar 06 '24Buy8.706,92060,204121,028Mar 08 04:05 PM
Emany Sravan KumarSVP, Chief Financial OfficerMar 04 '24Buy9.3810,684100,216301,733Mar 06 04:05 PM
MCCOURT Thomas AChief Executive OfficerFeb 12 '24Sale15.24177,1642,699,979832,774Feb 14 08:35 PM
John MinardoChief Legal OfficerFeb 12 '24Sale15.2447,380722,071224,796Feb 14 09:01 PM
Shetzline MichaelCMO,SVP,Head-Res&DrugFeb 12 '24Sale15.2438,618588,538340,484Feb 14 08:53 PM
Davis AndrewSVP, Chief Business OfficerFeb 12 '24Sale15.249,846150,053208,324Feb 14 08:42 PM
Silver RonaldPrincipal Accounting OfficerFeb 12 '24Sale15.247,908120,518134,264Feb 14 08:50 PM
Kessler Marla LDirectorDec 14 '23Sale11.199,926111,07296,572Dec 18 04:09 PM
Davis AndrewSVP, Chief Business OfficerNov 20 '23Sale9.693,28731,851217,374Nov 22 04:05 PM
Emany Sravan KumarSVP, Chief Financial OfficerSep 15 '23Buy8.3236,072300,119188,730Sep 18 05:07 PM
John MinardoChief Legal OfficerAug 14 '23Sale10.047,04570,732192,195Aug 16 04:20 PM
Silver RonaldPrincipal Accounting OfficerAug 14 '23Sale10.041,97619,839134,172Aug 16 04:21 PM
MCCOURT Thomas AChief Executive OfficerMay 30 '23Sale10.7026,632284,962758,284Jun 01 05:45 PM
MCCOURT Thomas AChief Executive OfficerMay 22 '23Sale10.1236,000364,320784,916May 24 04:05 PM
Shetzline MichaelCMO,SVP,Head-Res&DrugMay 22 '23Sale10.1210,324104,479321,131May 24 04:05 PM
Davis AndrewSVP, Chief Business OfficerMay 22 '23Sale10.126,30563,807219,327May 24 04:05 PM
MCCOURT Thomas AChief Executive OfficerMay 08 '23Sale10.6221,148224,592820,916May 10 04:05 PM